{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Liu HY"],"funding":["Key Project of the Guizhou Provincial Basic Research Program (Natural Science)","National Natural Science Foundation of China, Regional Science Fund Project"],"pagination":["423"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12604396"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["23(1)"],"pubmed_abstract":["<h4>Objective</h4>This study aims to compare the efficacy and safety of secondary cytoreductive surgery (SCS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) versus SCS alone in the management of platinum-sensitive recurrent ovarian cancer (PSROC) through a systematic review and meta-analysis.<h4>Methods</h4>A comprehensive search was performed in the PubMed, EMBASE, Web of Science, and Cochrane Library databases through December 31, 2024. Studies were eligible if they compared outcomes between individuals receiving SCS combined with HIPEC and those receiving SCS alone. The primary outcomes included progression-free survival (PFS) and overall survival (OS), measured using hazard ratios (HRs) with 95% confidence intervals (CIs). Secondary outcomes included the incidence of c"],"journal":["World journal of surgical oncology"],"pubmed_title":["Efficacy and safety of secondary cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in platinum-sensitive recurrent ovarian cancer: a systematic review and meta-analysis."],"pmcid":["PMC12604396"],"funding_grant_id":["ZD [2025] 023","82160538"],"pubmed_authors":["Liu HY","Huang G","Tian LH","Li N"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy and safety of secondary cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in platinum-sensitive recurrent ovarian cancer: a systematic review and meta-analysis.","description":"<h4>Objective</h4>This study aims to compare the efficacy and safety of secondary cytoreductive surgery (SCS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) versus SCS alone in the management of platinum-sensitive recurrent ovarian cancer (PSROC) through a systematic review and meta-analysis.<h4>Methods</h4>A comprehensive search was performed in the PubMed, EMBASE, Web of Science, and Cochrane Library databases through December 31, 2024. Studies were eligible if they compared outcomes between individuals receiving SCS combined with HIPEC and those receiving SCS alone. The primary outcomes included progression-free survival (PFS) and overall survival (OS), measured using hazard ratios (HRs) with 95% confidence intervals (CIs). Secondary outcomes included the incidence of c","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Nov","modification":"2026-06-05T15:00:17.993Z","creation":"2026-06-05T03:05:44.568Z"},"accession":"S-EPMC12604396","cross_references":{"pubmed":["41214655"],"doi":["10.1186/s12957-025-04076-7"]}}